Skip to content
15% off your first order15% off your first order

Tesamorelin vs CJC-1295

Tesamorelin and CJC-1295 are both growth-hormone-releasing hormone (GHRH) analogs studied for their action on pituitary GHRH receptors. Tesamorelin is described in research as a modified GHRH analog engineered for greater stability than the native hormone, and published reviews describe human clinical research on it, particularly on visceral adipose tissue in HIV-associated lipodystrophy. CJC-1295 without DAC, also called modified GRF 1-29, is characterized by a short half-life; without the drug affinity complex its action is brief, which research associates with preserving natural pulsatile growth hormone release. Human data for the no-DAC form are limited, appearing mainly in reviews and anti-doping detection research, while a small randomized trial studied the long-acting DAC form in healthy adults.